[1] Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening[J]. Sci Transl Med, 2019, 11:eaaw0064.
[2] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system:a summary[J]. Acta Neuropathol, 2016, 131:803-820.
[3] Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights:is there a glimmer of hope[J]? Neuro Oncology, 2017, 19:1025-1034.
[4] Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S, Barszczyk M, Chornenkyy Y, Bourgey M, Bourque G, Montpetit A, Cordero F, Castelo-Branco P, Mangerel J, Tabori U, Ho KC, Huang A, Taylor KR, Mackay A, Bendel AE, Nazarian J, Fangusaro JR, Karajannis MA, Zagzag D, Foreman NK, Donson A, Hegert JV, Smith A, Chan J, Lafay-Cousin L, Dunn S, Hukin J, Dunham C, Scheinemann K, Michaud J, Zelcer S, Ramsay D, Cain J, Brennan C, Souweidane MM, Jones C, Allis CD, Brudno M, Becher O, Hawkins C. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations[J]. Nat Genet, 2014, 46:451-456.
[5] Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F. Characteristics of H3 K27M-mutant gliomas in adults[J]. Neuro Oncology, 2017, 19:1127-1134.
[6] Jones C, Karajannis MA, Jones DT, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho Y, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA. Pediatric high-grade glioma:biologically and clinically in need of new thinking[J]. Neuro Oncology, 2017, 19:153-161.
[7] Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A, Zaky I, Elkhateeb N, Sabry M. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG):a randomized controlled trial[J]. Radiother Oncol, 2014, 111:35-40.
[8] El-Khouly FE, Veldhuijzen van Zanten SE, Santa-Maria Lopez V, Hendrikse NH, Kaspers GJ, Loizos G, Sumerauer D, Nysom K, Pruunsild K, Pentikainen V, Thorarinsdottir HK, Rutkauskiene G, Calvagna V, Drogosiewicz M, Dragomir M, Deak L, Kitanovski L, von Bueren AO, Kebudi R, Slavc I, Jacobs S, Jadrijevic-Cvrlje F, Entz-Werle N, Grill J, Kattamis A, Hauser P, Pears J, Biassoni V, Massimino M, Lopez Aguilar E, Torsvik IK, Joao Gil-da-Costa M, Kumirova E, Cruz-Martinez O, Holm S, Bailey S, Hayden T, Thomale UW, Janssens GO, Kramm CM, van Vuurden DG. Diagnostics and treatment of diffuse intrinsic pontine glioma:where do we stand[J]? J Neurooncol, 2019, 145:177-184.
[9] Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE. Phase Ⅱ trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas[J]. Neuro Oncol, 2011, 13:298-306.
[10] Janssens GO, Gidding CE, Van Lindert EJ, Oldenburger FR, Erasmus CE, Schouten-Meeteren AY, Kaanders JH. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children:a pilot study[J]. Int J Radiat Oncol Biol Phys, 2009, 73:722-726.
[11] Negretti L, Bouchireb K, Levy-Piedbois C, Habrand JL, Dhermain F, Kalifa C, Grill J, Dufour C. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children:a single institution's experience[J]. J Neurooncol, 2011, 104:773-777.
[12] Janssens GO, Jansen MH, Lauwers SJ, Nowak PJ, Oldenburger FR, Bouffet E, Saran F, Kamphuis-van Ulzen K, van Lindert EJ, Schieving JH, Boterberg T, Kaspers GJ, Span PN, Kaanders JH, Gidding CE, Hargrave D. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma:a matched-cohort analysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85:315-320. Laperriere N, Hukin J, Vanan MI,
[13] Lassaletta A, Strother D, Goddard K, Lafay-Cousin L, Johnston DL, Zelcer S, Zapotocky M, Rajagopal R, Ramaswamy V, Hawkins C, Tabori U, Huang A, Bartels U, Bouffet E. Reirradiation in patients with diffuse intrinsic pontine gliomas:the Canadian experience[J]. Pediatr Blood Cancer, 2018, 65:E26988.
[14] Veldhuijzen van Zanten SE, El-Khouly FE, Jansen MH, Bakker DP, Sanchez Aliaga E, Haasbeek CJ, Wolf NI, Zwaan CM, Vandertop WP, van Vuurden DG, Kaspers GJ. A phase Ⅰ/Ⅱ study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma[J]. J Neurooncol, 2017, 135:307-315.
[15] Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, Lemenuel-Diot A, Lopez-Diaz C, Kun L, Chintagumpala M, Su JM, Broniscer A, Baker JN, Hwang EI, Fouladi M, Boyett JM, Blaney SM. A pediatric brain tumor consortium phase Ⅱ trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas[J]. Pediatr Blood Cancer, 2018, 65:26832.
[16] Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas:a report from the Children's Oncology Group[J]. Neuro Oncology, 2011, 13:410-416.
[17] Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Innovative therapies for children with cancer pediatric phase Ⅰ study of erlotinib in brainstem glioma and relapsing/refractory brain tumors[J]. Neuro Oncology, 2011, 13:109-118.
[18] Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, Rutkowski S, Beilken A, Schmid I, Biassoni V, Gorelishev SK, Kramm C, Reinhard H, Schlegel PG, Kortmann RD, Reuter D, Bach F, Iznaga-Escobar NE, Bode U. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG):a phase Ⅲ clinical study[J]. J Neurooncol, 2019, 143:107-113.
[19] Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, Montero E. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities[J]. Hybridoma (Larchmt), 2007, 26:423-432.
[20] Diaz A, Leon K. Therapeutic approaches to target cancer stem cells[J]. Cancers (Basel), 2011, 3:3331-3352.
[21] Garrido G, Rabasa A, Garrido C, Chao L, Garrido F, García-Lora ÁM, Sánchez-Ramírez B. Upregulation of HLA class Ⅰ expression on tumor cells by the anti-EGFR antibody nimotuzumab[J]. Front Pharmacol, 2017, 8:595.
[22] Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J]. Clin Cancer Res, 2007, 13:1253-1259.
[23] Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma:a pediatric brain tumor consortium study[J]. J Clin Oncol, 2010, 28:3069-3075.
[24] Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201[J]. Oncotarget, 2016, 7:74380-74392.
[25] Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma:a case report[J]. J Neurosurg Pediatr, 2019, 5:1-7.
[26] Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers S, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong X, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201[J]. J Neurooncol, 2019, 145:97-105.
[27] Miao YF, Wang R, Jin YC, Yang SF, Wu H, Dai J, Li SQ, Zhang XH. Surgical treatment and molecular biological analysis of patients with glioma in cerebral midline area[J]. Shanghai Jiao Tong Da Xue Xue Bao (Yi Xue Ban), 2015, 35:1911-1914.[缪亦锋, 王冉, 金义超, 杨绍峰, 吴慧, 戴炯, 李善泉, 张晓华.脑中线部位胶质瘤的手术治疗及分子生物学分析[J]. 上海交通大学学报(医学版), 2015, 35:1911-1914.]
[28] Khatua S, Moore KR, Vats TS, Kestle JR. Diffuse intrinsic pontine glioma-current status and future strategies[J]. Childs Nerv Syst, 2011, 27:1391-1397.
[29] Zhou Z, Singh R, Souweidane MM. Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment[J]. Curr Neuropharmacol, 2017, 15:116-128.
[30] Wang AB, Tian C, Li YY, Zhao GM, Wang R, Gao YJ, Song Y, Lu JB, Liu YH, Han YX, Han HB. Advances in encephalopathy treatment with convection enhanced delivery via brain extracellular space[J]. Sheng Wu Yi Xue Gong Cheng Yu Lin Chuang, 2019, 23:481-486.[王艾博, 田灿, 李媛媛, 赵国梅, 王睿, 高亚娟, 宋宇, 卢嘉宾, 刘英慧, 韩易兴, 韩鸿宾. 经脑细胞外间隙途径对流增强给药在中枢神经系统疾病治疗中研究进展[J]. 生物医学工程与临床, 2019, 23:481-486.]
[31] Asthagiri AR, Walbridge S, Heiss JD, Lonser RR. Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer[J]. J Neurosurg, 2011, 115:467-473.
[32] Barua NU, Lowis SP, Woolley M, O'Sullivan S, Harrison R, Gill SS. Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma[J]. Acta Neurochir (Wien), 2013, 155:1459-1465.
[33] Heiss JD, Jamshidi A, Shah S, Martin S, Wolters PL, Argersinger DP, Warren KE, Lonser RR. Phase Ⅰ trial of convection-enhanced delivery of IL13-pseudomonas toxin in children with diffuse intrinsic pontine glioma[J]. J Neurosurg Pediatr, 2018, 23:333-342.
[34] Ivasyk I, Morgenstern PF, Wembacher-Schroeder E, Souweidane MM. Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery:case report[J]. J Neurosurg Pediatr, 2017, 20:256-260.
[35] Anderson RC, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, Feldstein NA, Bruce JN. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children[J]. J Neurosurg Pediatr, 2013, 11:289-295.
[36] Himes BT, Zhang L, Daniels DJ. Treatment strategies in diffuse midline gliomas with the H3K27M mutation:the role of convection-enhanced delivery in overcoming anatomic challenges[J]. Front Oncol, 2019, 9:31.
[37] Hashizume R. Epigenetic targeted therapy for diffuse intrinsic pontine glioma[J]. Neurol Med Chir (Tokyo), 2017, 57:331-342.
[38] Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma[J]. Nat Med, 2014, 20:1394-1396.
[39] Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y, Lamano JB, Carcaboso AM, Tian X, Seluanov A, Gorbunova V, Laurie KL, Kondo A, Wadhwani NR, Lulla R, Goldman S, Venneti S, Becher OJ, Zou L, Shilatifard A, Hashizume R. Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma[J]. Clin Cancer Res, 2019, 25:5572-5583.
[40] Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma[J]. Clin Cancer Res, 2008, 14:4500-4510.
[41] Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening[J]. Sci Transl Med, 2019, 11:eaaw0064.
[42] Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma[J]. Nat Med, 2015, 21:555-559.
[43] Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi Y, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas[J]. Nat Med, 2017, 23:493-500.
[44] Wang SS, Bandopadhayay P, Jenkins MR. Towards immunotherapy for pediatric brain tumors[J]. Trends Immunol, 2019, 40:748-761.
[45] O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJ, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRv Ⅲ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med, 2017, 9:eaaa984.
[46] Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T cells administered in combination with lymphodepletion·276·中国现代神经疾病杂志2020年4月第20卷第4期Chin J Contemp Neurol Neurosurg, April 2020, Vol. 20, No. 4 and PD-1 inhibition to patients with neuroblastoma[J]. Mol Ther, 2017, 25:2214-2224.
[47] Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas[J]. Nat Med, 2018, 24:572-579.
[48] Warren KE. Diffuse intrinsic pontine glioma:poised for progress[J]. Front Oncol, 2012, 2:205.
[49] Vanan MI, Eisenstat DD. DIPG in children:what can we learn from the past[J]? Front Oncol, 2015, 5:237.
[50] Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, Grill J, Boddaert N, Di Rocco F, Zerah M, Sainte-Rose C. Stereotactic biopsy of diffuse pontine lesions in children[J]. J Neurosurg, 2007, 107:1-4.
[51] El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019[J]. CA Cancer J Clin, 2019, 69:305-343.